123158-67-8 Usage
Uses
Used in Organic Synthesis:
N-(3-Bromo-5-ethylphenyl)acetamide is utilized as a key intermediate in various organic synthesis reactions. Its unique structure allows it to participate in a range of chemical transformations, making it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, N-(3-Bromo-5-ethylphenyl)acetamide serves as a crucial building block for the development of new drugs. Its structural features enable it to be modified and optimized for specific therapeutic targets, contributing to the discovery of novel pharmaceutical agents.
Used in Medicinal Chemistry:
N-(3-Bromo-5-ethylphenyl)acetamide has potential applications in the field of medicinal chemistry, where it can be employed for the design and synthesis of bioactive compounds. Its presence of a bromine atom and other functional groups allows for the exploration of its interactions with biological targets, potentially leading to the development of new therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 123158-67-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,3,1,5 and 8 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 123158-67:
(8*1)+(7*2)+(6*3)+(5*1)+(4*5)+(3*8)+(2*6)+(1*7)=108
108 % 10 = 8
So 123158-67-8 is a valid CAS Registry Number.
123158-67-8Relevant articles and documents
Kynurenic acid derivatives useful in the treatment of neurodegenerative disorders
-
, (2008/06/13)
4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, and their pharmaceutically acceptable salts, are potent specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment of neurodegenerative disorders. 4-Oxo-1,4-dihydroquinoline compounds having a 2-acidic group or a group convertible thereto in vivo, other than carboxy or C 1-6 alkoxycarbonyl, are novel compounds, as also are compounds of formula II STR1 wherein R 2 represents carboxy or a group convertible thereto in vivo, R 6 is hydrogen and R 5 and R 7 represent C 1-6 alkyl or halogen, provided that R 5 and R 7 are not simultaneously chlorine or simultaneously bromine; a process for preparing the novel compounds is described, as also are pharmaceutical compositions containing the novel compounds.
